There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Intec Pharma Ltd (NTEC) and HTG Molecular Diagnostics (HTGM) with bullish sentiments.
Intec Pharma Ltd (NTEC)
Ladenburg analyst Michael Higgins maintained a Buy rating on Intec Pharma Ltd yesterday and set a price target of $15. The company’s shares closed yesterday at $6.10.
Higgins observed:
“We believe this should occur in July, given management’s guidance of 8-12 weeks between end of trial and data, with 12 weeks being the week of July 22. As in prior updates, >90% of patients completing ACCORDANCE have opted to enroll in the one-year open-label extension. We believe this suggests patients feel better on AP-CD/LD and opt to continue on or return to this treatment. Recall, the trial is designed with two initial open-label titration periods for immediate-release CD/LD (Sinemet, the comparator), then AP-CD/LD. Therefore, patients know which drug worked better for them before entering the double-blind portion of the trial, with 90% of them deciding to continue into the OLE.”
According to TipRanks.com, Higgins ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -4.3% and a 33.5% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals Inc, Paratek Pharmaceuticals, and Zynerba Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Intec Pharma Ltd with a $14.33 average price target, representing a 134.9% upside. In a report released yesterday, Maxim Group also maintained a Buy rating on the stock with a $12 price target.
See today’s analyst top recommended stocks >>
HTG Molecular Diagnostics (HTGM)
Cantor Fitzgerald analyst Jordan Abrams maintained a Buy rating on HTG Molecular Diagnostics yesterday and set a price target of $6. The company’s shares closed yesterday at $2.50, close to its 52-week low of $2.03.
Abrams commented:
“We reaffirm our OW rating and think HTG’s EdgeSeq offers an attractive workflow solution that addresses key challenges in many existing molecular profiling technologies on the market. We view RNA-based panels as well-positioned to capitalize on trends in biomarker development, including faster turnaround time, lower sample-volume requirement, and next-gen sequencing (NGS)- based testing. We think shares of HTG will be rewarded with consistent product and service revenue acceleration along with a demonstrated growing pipeline of exclusive revenue-generating PDPs.”
According to TipRanks.com, Abrams is ranked #4560 out of 5198 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for HTG Molecular Diagnostics with a $6.33 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
